BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

6452 related articles for article (PubMed ID: 24756797)

  • 1. Trametinib.
    Zeiser R
    Recent Results Cancer Res; 2014; 201():241-8. PubMed ID: 24756797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trametinib (GSK1120212).
    Zeiser R; Andrlová H; Meiss F
    Recent Results Cancer Res; 2018; 211():91-100. PubMed ID: 30069762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trametinib (GSK1120212) in the treatment of melanoma.
    Salama AK; Kim KB
    Expert Opin Pharmacother; 2013 Apr; 14(5):619-27. PubMed ID: 23432625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition.
    Gilmartin AG; Bleam MR; Groy A; Moss KG; Minthorn EA; Kulkarni SG; Rominger CM; Erskine S; Fisher KE; Yang J; Zappacosta F; Annan R; Sutton D; Laquerre SG
    Clin Cancer Res; 2011 Mar; 17(5):989-1000. PubMed ID: 21245089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of the MEK inhibitor trametinib in the treatment of metastatic melanoma.
    King JW; Nathan PD
    Future Oncol; 2014; 10(9):1559-70. PubMed ID: 25145427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trametinib: a novel signal transduction inhibitor for the treatment of metastatic cutaneous melanoma.
    Chung C; Reilly S
    Am J Health Syst Pharm; 2015 Jan; 72(2):101-10. PubMed ID: 25550132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trametinib in metastatic melanoma.
    Chopra N; Nathan PD
    Expert Rev Anticancer Ther; 2015; 15(7):749-60. PubMed ID: 26107021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trametinib in the treatment of melanoma.
    Thota R; Johnson DB; Sosman JA
    Expert Opin Biol Ther; 2015 May; 15(5):735-47. PubMed ID: 25812921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.
    Menzies AM; Long GV
    Clin Cancer Res; 2014 Apr; 20(8):2035-43. PubMed ID: 24583796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MEK inhibitor trametinib does not prevent the growth of anaplastic lymphoma kinase (ALK)-addicted neuroblastomas.
    Umapathy G; Guan J; Gustafsson DE; Javanmardi N; Cervantes-Madrid D; Djos A; Martinsson T; Palmer RH; Hallberg B
    Sci Signal; 2017 Nov; 10(507):. PubMed ID: 29184034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allosteric MEK1/2 inhibitors including cobimetanib and trametinib in the treatment of cutaneous melanomas.
    Roskoski R
    Pharmacol Res; 2017 Mar; 117():20-31. PubMed ID: 27956260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma.
    Tolcher AW; Patnaik A; Papadopoulos KP; Rasco DW; Becerra CR; Allred AJ; Orford K; Aktan G; Ferron-Brady G; Ibrahim N; Gauvin J; Motwani M; Cornfeld M
    Cancer Chemother Pharmacol; 2015 Jan; 75(1):183-9. PubMed ID: 25417902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physapubescin B enhances the sensitivity of gastric cancer cells to trametinib by inhibiting the STAT3 signaling pathway.
    Dai C; Shen L; Jin W; Lv B; Liu P; Wang X; Yin Y; Fu Y; Liang L; Ma Z; Zhang X; Wang Y; Xu D; Chen Z
    Toxicol Appl Pharmacol; 2020 Dec; 408():115273. PubMed ID: 33035574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MEK Inhibitors in the Treatment of Metastatic Melanoma and Solid Tumors.
    Grimaldi AM; Simeone E; Festino L; Vanella V; Strudel M; Ascierto PA
    Am J Clin Dermatol; 2017 Dec; 18(6):745-754. PubMed ID: 28537004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MEK inhibitor GSK1120212-mediated radiosensitization of pancreatic cancer cells involves inhibition of DNA double-strand break repair pathways.
    Estrada-Bernal A; Chatterjee M; Haque SJ; Yang L; Morgan MA; Kotian S; Morrell D; Chakravarti A; Williams TM
    Cell Cycle; 2015; 14(23):3713-24. PubMed ID: 26505547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trametinib, a novel MEK kinase inhibitor, suppresses lipopolysaccharide-induced tumor necrosis factor (TNF)-α production and endotoxin shock.
    Shi-Lin D; Yuan X; Zhan S; Luo-Jia T; Chao-Yang T
    Biochem Biophys Res Commun; 2015 Mar; 458(3):667-673. PubMed ID: 25684183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trametinib: first global approval.
    Wright CJ; McCormack PL
    Drugs; 2013 Jul; 73(11):1245-54. PubMed ID: 23846731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trametinib in the treatment of multiple malignancies harboring MEK1 mutations.
    Lian T; Li C; Wang H
    Cancer Treat Rev; 2019 Dec; 81():101907. PubMed ID: 31715422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of MEK inhibitors in the treatment of metastatic melanoma.
    Grimaldi AM; Simeone E; Ascierto PA
    Curr Opin Oncol; 2014 Mar; 26(2):196-203. PubMed ID: 24419498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospects for MEK inhibitors for treating cancer.
    Martin-Liberal J; Lagares-Tena L; Larkin J
    Expert Opin Drug Saf; 2014 Apr; 13(4):483-95. PubMed ID: 24597490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 323.